Phase II evaluation of Aclacinomycin-A in advanced ovarian carcinoma


Sixteen women with advanced epithelial ovarian carcinoma were treated with Aclacinomycin-A 40 mg/M2 given as a weekly infusion for four consecutive weeks followed by a two week rest period. All had failed prior chemotherapy. No responses were observed. Nausea and vomiting were the most frequent side effect. Myelo-suppression was minimal. This dose and schedule of Aclacinomycin-A are not recommended for further trials in ovarian carcinoma.

DOI: 10.1007/BF00169977

1 Figure or Table

Cite this paper

@article{Martino1987PhaseIE, title={Phase II evaluation of Aclacinomycin-A in advanced ovarian carcinoma}, author={Silvana Martino and David A. Decker and Harry E. Hynes and Cynthia L. Kresge}, journal={Investigational New Drugs}, year={1987}, volume={5}, pages={373-374} }